Literature DB >> 25661647

Treatment Factors That Influence Mortality in Acromegaly.

John McCabe1, John Ayuk, Mark Sherlock.   

Abstract

Acromegaly is a rare condition characterized by excessive secretion of growth hormone (GH), which is almost always due to a pituitary adenoma. Acromegaly is associated with significant morbidity such as hypertension, type 2 diabetes, cardiomyopathy, obstructive sleep apnoea, malignancy and musculoskeletal abnormalities. Acromegaly has also been associated with increased mortality in several retrospective studies. This review will focus on the epidemiological data relating to mortality rates in acromegaly, the relationship between acromegaly and malignancy, the role of GH and insulin-like growth factor-I in assessing the risk of future mortality, and the impact of radiotherapy and hypopituitarism on mortality.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25661647     DOI: 10.1159/000375163

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  5 in total

1.  Two-dimensional speckle tracking echocardiography demonstrates no effect of active acromegaly on left ventricular strain.

Authors:  I C M Volschan; L Kasuki; C M S Silva; M L Alcantara; R M Saraiva; S S Xavier; M R Gadelha
Journal:  Pituitary       Date:  2017-06       Impact factor: 4.107

2.  Prescription patterns of long-acting somatostatin analogues.

Authors:  Jorge Enrique Machado-Alba; Manuel Enrique Machado-Duque
Journal:  SAGE Open Med       Date:  2017-03-09

3.  Twenty-four-hour growth hormone profiling in the assessment of acromegaly.

Authors:  Robert D'Arcy; C Hamish Courtney; Una Graham; Steven Hunter; David R McCance; Karen Mullan
Journal:  Endocrinol Diabetes Metab       Date:  2017-12-27

4.  Prevalence of comorbidities and concomitant medication use in acromegaly: analysis of real-world data from the United States.

Authors:  Maria Fleseriu; Ariel Barkan; Maria Del Pilar Schneider; Yannis Darhi; Amicie de Pierrefeu; Antonio Ribeiro-Oliveira; Stephan Petersenn; Sebastian Neggers; Shlomo Melmed
Journal:  Pituitary       Date:  2022-01-01       Impact factor: 4.107

Review 5.  Pasireotide: a novel treatment for patients with acromegaly.

Authors:  Daniel Cuevas-Ramos; Maria Fleseriu
Journal:  Drug Des Devel Ther       Date:  2016-01-11       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.